Pemafibrate

Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.

Product Specifications

CAS Number

[848259-27-8]

Product Name Alternative

(R) -K-13675

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Pemafibrate.html

Purity

99.88

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CC[C@@H](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)C(O)=O

Molecular Formula

C28H30N2O6

Molecular Weight

490.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Yamazaki Y, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett. 2007 Aug 15;17 (16) :4689-93. Epub2007 May 24.|[2]Honda Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 Feb 14;7:42477.|[3]Sairyo M, et al. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb. 2018 Feb 1;25 (2) :142-152.